Understanding how lectins affect the human microbiome and developing new treatments.
Characterization of lectins to understand human microbiome functions and develop live biotherapeutics
This study is looking at a special protein called Cbeg5 to see how it affects the way our immune cells interact with the bacteria in our gut, which could lead to new treatment options for people with inflammatory bowel disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11041142 on NIH RePORTER |
What this research studies
This research investigates the role of lectins, which are carbohydrate-binding proteins, in regulating interactions between human cells and the microbiome. By studying a specific lectin called Cbeg5, the research aims to uncover how it influences immune cell behavior and microbiome balance. The project will explore the potential of Cbeg5 as a therapeutic option for conditions like inflammatory bowel disease, utilizing advanced techniques in bioinformatics and cellular analysis. Patients may benefit from insights into how their microbiome functions and new treatment options that arise from this research.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals suffering from inflammatory bowel disease or those interested in the health of their microbiome.
Not a fit: Patients with conditions unrelated to microbiome function or those not affected by inflammatory bowel disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies for inflammatory bowel disease and improve our understanding of microbiome health.
How similar studies have performed: Previous research has shown promise in using lectins for therapeutic discovery, indicating that this approach may yield significant insights.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Cohen, Louis Jared — Icahn School of Medicine at Mount Sinai
- Study coordinator: Cohen, Louis Jared
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.